Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

Fig. 1

Decline in the use of anthracyclines to manage breast cancer [20]. Panels show monthly trends and fit curves of anthracycline and taxane use among a 4458 Medicare patients and b 30 422 Marketscan patients who were receiving adjuvant chemotherapy for breast cancer. Figure reproduced with permission [Copyright permission request is underway and the copyright line will be updated following manuscript acceptance]

Back to article page